271P Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study von Lopez Gonzalez, A., Del Barco Berron, S., Garau Llinas, I., Galan Gramaje, M., Castelo, B., Cortes Salgado, A., Sanchez-Rovira, P., Martinez Bueno, A., García, A., Gener, P., Mina, L., Alcalá, D., Sampayo-Cordero, M., Cortés, J., Perez Garcia, J.M., Llombart Cussac, A., Lopez Miranda, E.

Volltext